Second, our study enrolled more patients with adverse prognostic factors, such as PVTT (63.9%), main trunk of portal vein tumor thrombosis (Vp4) (27.8%), hepatocirrhosis (75.0%), viral hepatitis (87.1%), and higher AFP levels: 39.8% of patients with AFP ≥ 1,000 ng/mL, 50% of patients with AFP ≥ 400 ng/mL in our study, and 38% of patients with AFP ≥ 400 ng/mL in the IMbrave150 study (14). This evidence concerns the gene AFP and viral hepatitis.